• Urology

Hyung L. Kim, MD, is director of the Cedars-Sinai Academic Urology Program and associate director of Surgical Research in the Samuel Oschin Comprehensive Cancer Center. He has two professional passions. As a practicing urologic oncologist, Kim is devoted to promoting the physical and emotional health of his patients with cancers of the kidney, testis, prostate and bladder. His training includes fellowships in urologic oncology and minimally invasive surgery. He routinely provides treatments and second opinions for complex and difficult urologic cancer cases. Kim's second area of professional passion is his laboratory research, which has two areas of focus. The first area involves developing novel immune therapies for cancers. His lab is investigating the immune modulating effects of molecularly targeted therapies administered in combination with cancer vaccines. Heat shock protein-based cancer vaccines are used as model vaccines. Therapeutic goals include generating high-quality memory T cells and suppressing regulatory T cells. Kim's research also focuses on discovery and validation of clinically useful biomarkers for patients with urologic cancers. His laboratory has been developing new technology for generating multimarker expression profiles using archival tumors. His clinical work and research are highly complementary. Kim can offer his patients leading-edge treatment approaches, and the most challenging patient cases provide ideas and inspiration for his research.

• Medical School: University of Chicago Pritzker School of Medicine, 1996
• Internship: University of Chicago Medical Center, 1998
• Residency: University of Chicago Hospitals, 2002
• Fellowship: UCLA David Geffen School of Medicine, 2003
• Fellowship: UCLA David Geffen School of Medicine, 2004